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216* Allergic inﬂammation produces a hypersecretory airway ion
transport phenotype in mice
P. Anagnostopoulou1, L. Dai1, J. Duerr1, J. Schatterny1, S. Hirtz1, M.A. Mall1.
1Pediatric Pulmonology and Cystic Fibrosis Center, Department of Pediatrics III,
University of Heidelberg, Heidelberg, Germany
Abnormal airway ion transport plays a central role in the pathogenesis of cystic
ﬁbrosis (CF) lung disease. Cytokines released in allergic airway inﬂammation
(IL-4 and IL-13) have been reported to be potent mediators of ion transport in
airway epithelia in vitro. To determine the impact of allergic airway inﬂammation
on airway ion transport in vivo, we challenged BALB/c mice with a natural
aeroallergen, i.e. Aspergillus fumigatus extract (Af), by intratracheal instillation,
and studied the effects on ion transport in freshly excised airway tissues in Ussing
chambers, and on mRNA expression of the epithelial Na+ channel (ENaC) by real-
time RT-PCR. Af challenge induced a robust allergic airway inﬂammation with
elevated IL-13 and eosinophils in the airways. Amiloride-sensitive ENaC-mediated
Na+ absorption was signiﬁcantly reduced (DIsc−allergic = 22.2±3.2mA/cm2 vs.
DIsc−naive = 32.7±3.8mA/cm2, n = 18−21 per group, P< 0.05) and Ca2+-activated
(UTP-mediated) Cl− secretion was increased (DIsc−allergic = 72.8±11.0mA/cm2
vs. DIsc−naive = 45.8±7.0mA/cm2, n = 18−21 per group, P< 0.05) in lower airway
tissues from allergen-challenged compared with naive mice. Moreover, allergic
inﬂammation caused a signiﬁcant reduction in a, b, and gENaC expression.
We conclude that allergic inﬂammation inhibits ENaC-mediated Na+ absorption
and enhances CaCC-mediated Cl− secretion thereby producing a hypersecretory
phenotype in vivo. This could be of relevance for CF patients with confounding
allergic airway disease including allergic bronchopulmonary aspergillosis.
Supported by: Deutsche Forschungsgemeinschaft (DFG MA 2081/3−2), Ernest-
Solvay-Stiftung (T077/17752/08).
217* Accumulation of NKT cells in tissues of cystic ﬁbrosis mice
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In lung tissues of patients suffering from cystic ﬁbrosis (CF), a hereditary disease
caused by mutations in the membrane bound chloride channel CFTR, and in unin-
fected CF mice, we have detected an abnormal accumulation of ceramide (Teich-
gra¨ber et al., Nature Med 2008;14:382). Ceramide accumulation provoked an age-
dependent recruitment of macrophages and neutrophils in lungs of uninfected CF
mice which was abrogated by administration of amitriptyline, a blocker of acid
sphin-gomyelinase. Since endogenous glycolipids are known to trigger NKT cell
maturation and proliferation, we hypothesized that ceramide accumulation also
triggers NKT cell accumulation in tissues of CF mice, expressing mutated CFTR
such as the intestine and lungs, but not in CFTR-negative tissues such as the liver.
We homogenized in-testine, liver and lungs of CF and control mice at various ages
(12−91 weeks), iso-lated the T cell fraction and quantitatively determined NKT
cells using CD1 d-aGalCer tetramer-staining. We present evidence that the numbers
of NKT cells present in the intestine and lungs of CF mice are signiﬁcantly higher
compared to wild type (WT) mice (NKT intestine CF: 5.36×104 NKT cells; WT:
3.33×103; lung CF: 8.14×104 NKT cells; WT: 1.92x104). No difference was
observed in the liver (NKT liver CF: 7.76×105 NKT cells; WT: 7.16x105). The
results suggest that CF mice represent a new animal model for testing NKT cell
functions and drugs with anti-NKT cell activity.
218* Azithromycin is not able to decrease inﬂammatory process in
cystic ﬁbrosis human bronchial epithelial cells
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Objective: The aim of this study was to explore the effects of macrolides:
azithromycin (AZM), clarithromycin (CAM) and erythromycin (EM) on molecular
mechanisms involved during inﬂammation in bronchial epithelial cystic ﬁbrosis
(CF) cells.
Methods: Human CF bronchial epithelial (IB3−1) and CFTR-corrected bronchial
epithelial cell lines (S9) were pre-treated 30 minutes with the macrolide (10 mg/ml)
and TNF-a (10 ng/ml) was added for additional 16 h of culture. To conﬁrm results,
we have treated with the same protocol human bronchial gland cells (HBG) isolated
from non-CF patients with or without the CFTR inhibitor Inh-172 (10 mM, 72 h).
IL-8 concentrations were evaluated in culture supernatants by ELISA and NF-úB
pathway was investigated by a p65-luciferase plasmid at 4 h and 8 h of treatment.
Results: CAM and EM were not able to modulate TNF-a induced IL-8 secretion.
Interestingly AZM signiﬁcantly reduced TNF-a induced IL-8 secretion in non-
CF cells (S9 and HBG cells) but not in CF cells (IB3−1 cells and HBG cells
treated with the CFTR inhibitor Inh-172). Next, we have investigated molecular
mechanisms after 4 h and 8 h of treatment. We have demonstrated that AZM
signiﬁcantly decreased TNF-a induced NF-úB transcriptionnal activity in S9 but
not in IB3−1 cell line.
Conclusion: Our study demonstrates that azithromycin is not able to decrease
inﬂammation in CF bronchial epithelial cells and suggests that CFTR chloride
function may be involved in normal cells response to AZM.
Supported in part by the French Association Vaincre La Mucoviscidose. We also
thank Pﬁzer Laboratories for their generous gift of azithromycin.
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Background: Lung dysfunction is the main cause of mortality in CF patients.
Infection combined with inﬂammation lead to progressive destruction of respiratory
epithelium. Glucocorticoids (GC) are powerful anti-inﬂammatory molecules com-
monly used to treat inﬂammation but with controversial efﬁciency among studies.
Recent clinical trials showed that inhaled and oral corticosteroids have no signiﬁcant
effect on lung function or markers of inﬂammation. These results were conﬁrmed
in in vitro studies using cell lines and primary cell cultures from CF patients.
Our project focuses on the key steps in GC activation pathway in bronchial epithelial
cells to characterise the molecular basis of such dysregulation.
Methods: CF and non CF bronchial epithelial cell lines were incubated with IL-1b
or TNF-a (10 ng/ml) at 4 h, 8 h, and 16 h with or without dexamethasone (dex,
1mM). Rates of secreted IL-8 were assessed by ELISA 16 h after treatment. To
evaluate NF-úB or AP-1 activation at 4 h and 8 h, we transfected cells using plasmids
contening NF-úB or AP-1 promoter coupled to luciferase.
Results: In presence of IL-1b, basal secretion of IL-8 was restored by dex at 16 h
in non CF cells, whereas CF cells barely respond. Other results showed there is no
effect of dex on NF-úB activation at 8 h in CF cells.
Conclusions: This study shows a lack of GC efﬁciency to decrease IL-8 secretion
via NF-úB pathway in CF bronchial epithelial cells.
Identify the origin of the GC resistance in CF will allow to adapt the anti-
inﬂammatory treatments of patients.
Supported by: UPMC and the French Cystic Fibrosis association Vaincre La
Mucoviscidose.
